Bioengineered miR-148a-3p suppresses glycolysis and amino acid homeostasis in hepatocellular carcinoma cells by regulating multiple solute carrier transporters
Open Access
- 1 June 2026
- journal article
- Published by KEAI Publishing in Liver Research
- Vol. 10 (2) , 166-176
Abstract
Hepatocellular carcinoma (HCC) cells are metabolically reprogrammed for excessive uptake and metabolism of many nutrients. The tumor suppressive microRNA-148a-3p (miR-148a-3p) is downregulated in HCC, whereas its function in regulating HCC cell metabolism remains obscure. Herein we aimed to delineate the role of miR-148a-3p in HCC cell metabolism by using novel bioengineered miR-148a-3p (BioRNALeu/miR-148a-3p) agent produced in vivo. BioRNALeu/miR-148a-3p was designed by using human leucyl transfer RNA fused hsa-pre-miR-34a carrier, overexpressed in Escherichia coli (E. coli), and purified to high homogeneity. After transfection into HCC cells, the released miR-148a-3p levels were assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Cell proliferation was determined by CellTiter-Glo assays. Targets were validated by dual-luciferase reporter assays, immunoblotting, and immunofluorescence confocal imaging. Glycolysis capacity was evaluated by Seahorse XF assays, and glucose, lactate, and amino acid levels were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods. BioRNALeu/miR-148a-3p was efficiently processed into target miR-148a-3p in HCC cells to effectively inhibit cell proliferation in a dose- and time-dependent manner. Mechanistically, miR-148a-3p suppressed the protein levels of glucose transporter GLUT1/SLC2A1 and L-type amino acid transporter LAT1/SLC7A5 via acting on their 3′-untranslated regions, as well as amino acid transporter ASCT2/SLC1A5. These, in turn, led to a reduction of glucose uptake, lactate production, and glycolytic flux in HCC cells, and alteration of intracellular amino acid metabolome including glutamine, leucine, phenylalanine, tyrosine, and methionine. Reintroduction of miR-148a-3p into HCC cells modulates glucose and amino acid metabolism via regulating multiple SLC transporters, thereby suppressing HCC cell viability. These findings highlight the role of miR-148a-3p in HCC cell metabolism and potential of bioengineered miRNA molecules for functional studies and therapeutic development.Keywords
Funding Information
- National Cancer Institute (P30CA093373)
- National Cancer Institute (R01CA225958)
- National Cancer Institute (R01CA291771)
- National Institutes of Health
- National Institute of General Medical Sciences (R35GM140835)
- University of California, Davis (P30CA093373)
This publication has 59 references indexed in Scilit:
- MicroRNA-148a-3p suppresses the glycolysis and Cell proliferation by targeting transmembrane protein 54 in liver cancerBiochemical and Biophysical Research Communications, 2023
- Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancerActa Pharmaceutica Sinica B, 2023
- Identification of the prognostic, diagnostic, and biological significance of the miR‐148a‐3p/cathepsin A axis in hepatocellular carcinomaJournal of Biochemical and Molecular Toxicology, 2022
- Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivoActa Pharmaceutica Sinica B, 2021
- Expression and Purification of tRNA/pre-miRNA-Based Recombinant Noncoding RNAs2021
- Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growthBiochemical Pharmacology, 2021
- Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and diseasePflügers Archiv - European Journal of Physiology, 2020
- Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeuticsActa Pharmaceutica Sinica B, 2020
- Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expressionActa Pharmaceutica Sinica B, 2019
- miR‐148b inhibits glycolysis in gastric cancer through targeting SLC2A1Cancer Medicine, 2017